Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024)

Immunocore Holdings (IMCR) has disclosed Other Accumulated Expenses for 3 consecutive years, with $7.5 million as the latest value for Q1 2024.

  • Quarterly Other Accumulated Expenses changed N/A to $7.5 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Mar 2024, changed N/A year-over-year, with the annual reading at $6.0 million for FY2023, 62.74% up from the prior year.
  • Other Accumulated Expenses hit $7.5 million in Q1 2024 for Immunocore Holdings, up from $6.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $7.5 million in Q1 2024 to a low of $3.7 million in Q4 2022.
  • Historically, Other Accumulated Expenses has averaged $5.7 million across 3 years, with a median of $6.0 million in 2023.
  • Biggest YoY gain for Other Accumulated Expenses was 62.74% in 2023; the steepest drop was 62.74% in 2023.
  • Year by year, Other Accumulated Expenses stood at $3.7 million in 2022, then surged by 62.74% to $6.0 million in 2023, then increased by 24.49% to $7.5 million in 2024.
  • Business Quant data shows Other Accumulated Expenses for IMCR at $7.5 million in Q1 2024, $6.0 million in Q4 2023, and $3.7 million in Q4 2022.